$NEUE
NeueHealth, Inc. Stock $neue

$neue Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000162828023017232 Filed on May 10, 2023

Income Statement

Concept	2023 Q2	2023 Q1
Revenue	$298.0M	$756.3M
YoY Change	-81.1%	-58.8%
Cost Of Revenue	$245.2M	$260.1M
YoY Change
Gross Profit	$52.82M	$496.2M
YoY Change
Gross Profit Margin	17.73%	65.61%
Selling, General & Admin	$70.28M	$140.3M
YoY Change	-83.0%	-66.5%
% of Gross Profit	133.05%	28.28%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$6.135M	$9.891M
YoY Change	-53.62%	-24.15%
% of Gross Profit	11.61%	1.99%
Operating Expenses	$321.4M	$842.1M
YoY Change	-82.39%	-58.16%
Operating Profit	-$23.41M	-$85.75M
YoY Change	-90.56%	-51.55%
Interest Expense	$9.170M	$7.787M
YoY Change	2621.07%	552.72%
% of Operating Profit
Other Income/Expense, Net	$0.00	$0.00
YoY Change	-100.0%	-100.0%
Pretax Income	-$32.58M	-$93.53M
YoY Change	-86.88%	-47.27%
Income Tax	-$900.0K	$1.300M
% Of Pretax Income
Net Earnings	-$112.8M	-$175.0M
YoY Change	-58.92%	-10.36%
Net Earnings / Revenue	-37.87%	-23.14%
Basic Earnings Per Share	-$15.70	-$0.30
Diluted Earnings Per Share	-$15.70	-$0.30
COMMON SHARES
Basic Shares Outstanding	636.1M shares	630.3M shares
Diluted Shares Outstanding	7.962M shares	631.5M shares

Balance Sheet

Concept	2023 Q2	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents	$107.7M	$382.5M
Short-Term Investments
Other Short-Term Assets	$61.20M	$142.9M
YoY Change	-82.91%	-54.69%
Inventory
Prepaid Expenses
Receivables	$27.63M	$125.2M
Other Receivables
Total Short-Term Assets	$3.851B	$3.771B
YoY Change	21.86%	14.47%
LONG-TERM ASSETS
Property, Plant & Equipment	$18.47M	$40.75M
YoY Change	-61.46%	-1.29%
Goodwill	$401.4M	$760.1M
YoY Change	-51.96%	-9.02%
Intangibles	$99.08M	$242.3M
YoY Change	-68.67%	-25.82%
Long-Term Investments	$344.0K	$3.816M
YoY Change	-99.96%	-99.48%
Other Assets	$22.74M	$29.66M
YoY Change	-42.19%	-31.71%
Total Long-Term Assets	$542.0M	$1.077B
YoY Change	-74.2%	-45.63%
TOTAL ASSETS
Total Short-Term Assets	$3.851B	$3.771B
Total Long-Term Assets	$542.0M	$1.077B
Total Assets	$4.393B	$4.848B
YoY Change	-16.5%	-8.1%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$18.48M	$33.64M
YoY Change	-84.67%	-73.8%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$303.9M	$303.9M
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.635B	$4.012B
YoY Change	0.11%	18.38%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$28.79M	$32.19M
YoY Change	-20.22%	-17.14%
Total Long-Term Liabilities	$28.79M	$32.19M
YoY Change	-20.22%	-17.14%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.635B	$4.012B
Total Long-Term Liabilities	$28.79M	$32.19M
Total Liabilities	$3.664B	$4.044B
YoY Change	-0.09%	17.98%
SHAREHOLDERS EQUITY
Retained Earnings	-$3.444B	-$3.331B
YoY Change	58.67%	75.7%
Common Stock	$1.000K	$63.00K
YoY Change	-98.41%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$435.7M	-$340.0M
YoY Change
Total Liabilities & Shareholders Equity	$4.393B	$4.848B
YoY Change	-16.5%	-8.1%

Cashflow Statement

Concept	2023 Q2	2023 Q1
OPERATING ACTIVITIES
Net Income	-$112.8M	-$175.0M
YoY Change	-58.92%	-10.36%
Depreciation, Depletion And Amortization	$6.135M	$9.891M
YoY Change	-53.62%	-24.15%
Cash From Operating Activities	-$109.0M	-$615.0M
YoY Change	-145.06%	-226.87%
INVESTING ACTIVITIES
Capital Expenditures	$531.0K	$1.863M
YoY Change	-105.5%	-66.07%
Acquisitions		$0.00
YoY Change		-100.0%
Other Investing Activities	-$529.1M	$688.7M
YoY Change	71.35%	-209.72%
Cash From Investing Activities	-$529.7M	$686.8M
YoY Change	66.32%	-208.48%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-3.146M	-$1.804M
YoY Change	112.71%	-100.3%
NET CHANGE
Cash From Operating Activities	-109.0M	-$615.0M
Cash From Investing Activities	-529.7M	$686.8M
Cash From Financing Activities	-3.146M	-$1.804M
Net Change In Cash	-641.8M	$69.96M
YoY Change	722.52%	-84.26%
FREE CASH FLOW
Cash From Operating Activities	-$109.0M	-$615.0M
Capital Expenditures	$531.0K	$1.863M
Free Cash Flow	-$109.5M	-$616.9M
YoY Change	-143.54%	-228.71%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001671284
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://fasb.org/us-gaap/2022#ServiceMember
CY2022Q1	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://fasb.org/us-gaap/2022#ServiceMember
CY2022Q1	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://fasb.org/us-gaap/2022#ServiceMember
CY2023Q1	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://fasb.org/us-gaap/2022#ServiceMember
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-40537
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	BRIGHT HEALTH GROUP, INC.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-4991296
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	8000 Norman Center Drive, Suite 900
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Minneapolis
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	MN
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	55437
CY2023Q1	dei	City Area Code CityAreaCode	612
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	238-1321
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value
CY2023Q1	dei	Trading Symbol TradingSymbol	BHG
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NYSE
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	636146133	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	382506000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	466325000	usd
CY2023Q1	us-gaap	Short Term Investments ShortTermInvestments	12112000	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	13206000	usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	6513000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	6098000	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	125241000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	73605000	usd
CY2023Q1	bhg	Aco Reach Performance Year Receivable Current ACOReachPerformanceYearReceivableCurrent	882884000	usd
CY2022Q4	bhg	Aco Reach Performance Year Receivable Current ACOReachPerformanceYearReceivableCurrent	99181000	usd
CY2023Q1	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	2225739000	usd
CY2022Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	2783474000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	142932000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	134843000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	3771414000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	3570634000	usd
CY2023Q1	us-gaap	Long Term Investments LongTermInvestments	3816000	usd
CY2022Q4	us-gaap	Long Term Investments LongTermInvestments	5401000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	40747000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	42596000	usd
CY2023Q1	us-gaap	Goodwill Goodwill	760078000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	760078000	usd
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	242286000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	249083000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	29664000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	37260000	usd
CY2023Q1	us-gaap	Assets Noncurrent AssetsNoncurrent	1076591000	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	1094418000	usd
CY2023Q1	us-gaap	Assets Assets	4848005000	usd
CY2022Q4	us-gaap	Assets Assets	4665052000	usd
CY2023Q1	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	458465000	usd
CY2022Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	411753000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	33638000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	67854000	usd
CY2023Q1	us-gaap	Unearned Premiums UnearnedPremiums	139416000	usd
CY2022Q4	us-gaap	Unearned Premiums UnearnedPremiums	242000	usd
CY2023Q1	bhg	Aco Reach Performance Year Obligation Current ACOReachPerformanceYearObligationCurrent	719420000	usd
CY2022Q4	bhg	Aco Reach Performance Year Obligation Current ACOReachPerformanceYearObligationCurrent	0	usd
CY2023Q1	us-gaap	Short Term Borrowings ShortTermBorrowings	303947000	usd
CY2022Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	303947000	usd
CY2023Q1	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	2225739000	usd
CY2022Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	2783474000	usd
CY2023Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	131256000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	121424000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	4011881000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3688694000	usd
CY2023Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	32191000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	36673000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	4044072000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	3725367000	usd
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q1	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	223503000	usd
CY2022Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	219758000	usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	3000000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	3000000000	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	636142597	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	636142597	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	630271508	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	630271508	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	63000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	63000	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	3005592000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2972271000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-3331406000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-3156395000	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2236000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4429000	usd
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	2522148	shares
CY2023Q1	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	2522148	shares
CY2023Q1	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	12000000	usd
CY2022Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	12000000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-339987000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-200490000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4848005000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4665052000	usd
CY2023Q1	us-gaap	Premiums Earned Net PremiumsEarnedNet	502918000	usd
CY2022Q1	us-gaap	Premiums Earned Net PremiumsEarnedNet	458962000	usd
CY2023Q1	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	239807000	usd
CY2022Q1	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	182797000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	13570000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	12392000	usd
CY2023Q1	bhg	Investment Income Loss InvestmentIncomeLoss	46000	usd
CY2022Q1	bhg	Investment Income Loss InvestmentIncomeLoss	-40888000	usd
CY2023Q1	us-gaap	Revenues Revenues	756341000	usd
CY2022Q1	us-gaap	Revenues Revenues	613263000	usd
CY2023Q1	us-gaap	Policyholder Benefits And Claims Incurred Health Care PolicyholderBenefitsAndClaimsIncurredHealthCare	688515000	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-160272000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1259000	usd
CY2022Q1	us-gaap	Policyholder Benefits And Claims Incurred Health Care PolicyholderBenefitsAndClaimsIncurredHealthCare	594248000	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	140324000	usd
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	159117000	usd
CY2023Q1	us-gaap	Restructuring Charges RestructuringCharges	3357000	usd
CY2022Q1	us-gaap	Restructuring Charges RestructuringCharges	6864000	usd
CY2023Q1	bhg	Depreciation Depletion And Amortization Continuing Operations DepreciationDepletionAndAmortizationContinuingOperations	9891000	usd
CY2022Q1	bhg	Depreciation Depletion And Amortization Continuing Operations DepreciationDepletionAndAmortizationContinuingOperations	12897000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	842087000	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	773126000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-85746000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-159863000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	7787000	usd
CY2022Q1	us-gaap	Interest Expense InterestExpense	1193000	usd
CY2023Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	0	usd
CY2022Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	784000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-93533000	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3242000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-94792000	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-163514000	usd
CY2023Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-74669000	usd
CY2022Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-17115000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-169461000	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-180629000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Attributable To Noncontrolling Entity IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity	5550000	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Attributable To Noncontrolling Entity IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity	14605000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-186905000	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-204172000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.18
CY2023Q1	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.18
CY2022Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.30
CY2022Q1	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.30
CY2023Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.12
CY2023Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.12
CY2022Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.02
CY2022Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.02
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.30
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.30
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.32
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.32
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	631534000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	631534000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	628765000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	628765000	shares
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-169461000	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-180629000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0	usd
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0	usd
CY2022Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0	usd
CY2022Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0	usd
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1729000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-28089000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax	0	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax	0	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax	0	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax	0	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	-464000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	-1749000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	2193000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-26340000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-167268000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-206969000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	5550000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	14605000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-172818000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-221574000	usd
CY2022Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	925000	shares
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	920417000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-200490000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-175011000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	33320000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	2193000	usd
CY2023Q1	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	925000	shares
CY2023Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	920417000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-339987000	usd
CY2021Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2021Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	1145120000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-195234000	usd
CY2022Q1	bhg	Temporary Equity Stock Issued During Period Shares New Issues TemporaryEquityStockIssuedDuringPeriodSharesNewIssues	750000	shares
CY2022Q1	us-gaap	Temporary Equity Stock Issued During Period Value New Issues TemporaryEquityStockIssuedDuringPeriodValueNewIssues	747481000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	257000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	32921000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-26340000	usd
CY2022Q1	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	750000	shares
CY2022Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	747481000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	956724000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-169461000	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-180629000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	9891000	usd
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	13041000	usd
CY2023Q1	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	usd
CY2022Q1	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	6720000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	33320000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	32921000	usd
CY2023Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	436000	usd
CY2022Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	717000	usd
CY2023Q1	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	0	usd
CY2022Q1	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-40968000	usd
CY2023Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	2807000	usd
CY2022Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-2378000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	43409000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	29221000	usd
CY2023Q1	bhg	Increase Decrease In Direct Contracting Performance Year Receivable IncreaseDecreaseInDirectContractingPerformanceYearReceivable	783703000	usd
CY2022Q1	bhg	Increase Decrease In Direct Contracting Performance Year Receivable IncreaseDecreaseInDirectContractingPerformanceYearReceivable	638641000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-22448000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	22270000	usd
CY2023Q1	us-gaap	Increase Decrease In Liability For Claims And Claims Adjustment Expense Reserve IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve	-423459000	usd
CY2022Q1	us-gaap	Increase Decrease In Liability For Claims And Claims Adjustment Expense Reserve IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve	337180000	usd
CY2023Q1	bhg	Increase Decrease In Risk Adjustment Payable IncreaseDecreaseInRiskAdjustmentPayable	4153000	usd
CY2022Q1	bhg	Increase Decrease In Risk Adjustment Payable IncreaseDecreaseInRiskAdjustmentPayable	354276000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	-119416000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	52182000	usd
CY2023Q1	us-gaap	Increase Decrease In Unearned Premiums IncreaseDecreaseInUnearnedPremiums	137563000	usd
CY2022Q1	us-gaap	Increase Decrease In Unearned Premiums IncreaseDecreaseInUnearnedPremiums	-18402000	usd
CY2023Q1	bhg	Increase Decrease In Direct Contracting Performance Year Obligation IncreaseDecreaseInDirectContractingPerformanceYearObligation	719420000	usd
CY2022Q1	bhg	Increase Decrease In Direct Contracting Performance Year Obligation IncreaseDecreaseInDirectContractingPerformanceYearObligation	533537000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-615024000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	484757000	usd
CY2023Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	2880000	usd
CY2022Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	782091000	usd
CY2023Q1	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	690161000	usd
CY2022Q1	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	154765000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1863000	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5491000	usd
CY2023Q1	us-gaap	Proceeds From Divestiture Of Businesses Net Of Cash Divested ProceedsFromDivestitureOfBusinessesNetOfCashDivested	1370000	usd
CY2022Q1	us-gaap	Proceeds From Divestiture Of Businesses Net Of Cash Divested ProceedsFromDivestitureOfBusinessesNetOfCashDivested	0	usd
CY2023Q1	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	usd
CY2022Q1	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	310000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	686788000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-633127000	usd
CY2023Q1	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	0	usd
CY2022Q1	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	155000000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Redeemable Preferred Stock ProceedsFromIssuanceOfRedeemablePreferredStock	0	usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Redeemable Preferred Stock ProceedsFromIssuanceOfRedeemablePreferredStock	747481000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1000	usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	257000	usd
CY2023Q1	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	1805000	usd
CY2022Q1	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	0	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1804000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	592738000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	69960000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	444368000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1932290000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1061179000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2002250000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1505547000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	2193000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-26340000	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	7157000	usd
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	1168000	usd
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our condensed consolidated financial statements in conformance with GAAP requires management to make estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. Our most significant estimates include medical costs payable, risk adjustment revenue and associated payables and receivables, premium deficiency reserve, ACO REACH performance year receivable and obligation, and valuation and impairment of goodwill and other intangible assets. Actual results could differ from these estimate</span>s.
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-169500000	usd
CY2022Q4	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	175000000	usd
CY2023Q1	us-gaap	Labor And Related Expense LaborAndRelatedExpense	85208000	usd
CY2022Q1	us-gaap	Labor And Related Expense LaborAndRelatedExpense	96216000	usd
CY2023Q1	us-gaap	Professional Fees ProfessionalFees	12687000	usd
CY2022Q1	us-gaap	Professional Fees ProfessionalFees	14739000	usd
CY2023Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	20344000	usd
CY2022Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	18382000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10974000	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	15942000	usd
CY2023Q1	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	11111000	usd
CY2022Q1	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	13838000	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	140324000	usd
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	159117000	usd
CY2023Q1	us-gaap	Severance Costs1 SeveranceCosts1	-760000	usd
CY2023Q1	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	880000	usd
CY2023Q1	bhg	Contract Termination And Other Costs ContractTerminationAndOtherCosts	3237000	usd
CY2023Q1	us-gaap	Restructuring Charges RestructuringCharges	3357000	usd
CY2023Q1	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	900000	usd
CY2022Q1	us-gaap	Severance Costs1 SeveranceCosts1	6097000	usd
CY2022Q1	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2022Q1	bhg	Contract Termination And Other Costs ContractTerminationAndOtherCosts	767000	usd
CY2022Q1	us-gaap	Restructuring Charges RestructuringCharges	6864000	usd
CY2022Q4	us-gaap	Restructuring Reserve RestructuringReserve	24592000	usd
CY2023Q1	us-gaap	Restructuring Reserve Accrual Adjustment1 RestructuringReserveAccrualAdjustment1	1716000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	6800000	usd
CY2023Q1	us-gaap	Payments For Restructuring PaymentsForRestructuring	9839000	usd
CY2023Q1	us-gaap	Restructuring Reserve RestructuringReserve	13037000	usd
CY2023Q1	bhg	Cash Cash Equivalents Available For Sale And Held To Maturity Securities Amortized Cost CashCashEquivalentsAvailableForSaleAndHeldToMaturitySecuritiesAmortizedCost	382510000	usd
CY2023Q1	bhg	Cash Cash Equivalents Available For Sale And Held To Maturity Securities Accumulated Gross Unrealized Gain Before Tax CashCashEquivalentsAvailableForSaleAndHeldToMaturitySecuritiesAccumulatedGrossUnrealizedGainBeforeTax	5000	usd
CY2023Q1	bhg	Cash Cash Equivalents Available For Sale And Held To Maturity Securities Accumulated Gross Unrealized Loss Before Tax CashCashEquivalentsAvailableForSaleAndHeldToMaturitySecuritiesAccumulatedGrossUnrealizedLossBeforeTax	9000	usd
CY2023Q1	bhg	Cash Cash Equivalents Available For Sale And Held To Maturity Securities CashCashEquivalentsAvailableForSaleAndHeldToMaturitySecurities	382506000	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	14033000	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	5000	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	292000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	13746000	usd
CY2023Q1	us-gaap	Debt Securities Held To Maturity Amortized Cost After Allowance For Credit Loss DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss	2182000	usd
CY2023Q1	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Gain HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain	0	usd
CY2023Q1	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Loss HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss	0	usd
CY2023Q1	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	2182000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale And Held To Maturity Amortized Cost After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss	398725000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale And Held To Maturity Cumulative Unrecognized Gain DebtSecuritiesAvailableForSaleAndHeldToMaturityCumulativeUnrecognizedGain	10000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale And Held To Maturity Cumulative Unrecognized Loss DebtSecuritiesAvailableForSaleAndHeldToMaturityCumulativeUnrecognizedLoss	301000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale And Held To Maturity Fair Value DebtSecuritiesAvailableForSaleAndHeldToMaturityFairValue	398434000	usd
CY2022Q4	bhg	Cash Cash Equivalents Available For Sale And Held To Maturity Securities Amortized Cost CashCashEquivalentsAvailableForSaleAndHeldToMaturitySecuritiesAmortizedCost	340795000	usd
CY2022Q4	bhg	Cash Cash Equivalents Available For Sale And Held To Maturity Securities Accumulated Gross Unrealized Gain Before Tax CashCashEquivalentsAvailableForSaleAndHeldToMaturitySecuritiesAccumulatedGrossUnrealizedGainBeforeTax	8000	usd
CY2022Q4	bhg	Cash Cash Equivalents Available For Sale And Held To Maturity Securities Accumulated Gross Unrealized Loss Before Tax CashCashEquivalentsAvailableForSaleAndHeldToMaturitySecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	usd
CY2022Q4	bhg	Cash Cash Equivalents Available For Sale And Held To Maturity Securities CashCashEquivalentsAvailableForSaleAndHeldToMaturitySecurities	340803000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	16390000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	413000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	15978000	usd
CY2022Q4	us-gaap	Debt Securities Held To Maturity Amortized Cost After Allowance For Credit Loss DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss	2632000	usd
CY2022Q4	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Gain HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain	0	usd
CY2022Q4	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Loss HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss	0	usd
CY2022Q4	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	2632000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale And Held To Maturity Amortized Cost After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss	359817000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale And Held To Maturity Cumulative Unrecognized Gain DebtSecuritiesAvailableForSaleAndHeldToMaturityCumulativeUnrecognizedGain	9000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale And Held To Maturity Cumulative Unrecognized Loss DebtSecuritiesAvailableForSaleAndHeldToMaturityCumulativeUnrecognizedLoss	413000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale And Held To Maturity Fair Value DebtSecuritiesAvailableForSaleAndHeldToMaturityFairValue	359413000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	800	investment
CY2023Q1	bhg	Debt Securities Available For Sale Number Of Investments DebtSecuritiesAvailableForSaleNumberOfInvestments	1340	investment
CY2022Q4	bhg	Debt Securities Available For Sale And Held To Maturity Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleAndHeldToMaturityUnrealizedLossPositionNumberOfPositions	721	investment
CY2022Q4	bhg	Debt Securities Available For Sale And Held To Maturity Number Of Investments DebtSecuritiesAvailableForSaleAndHeldToMaturityNumberOfInvestments	2432	investment
CY2023Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	10343000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	10187000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	3611000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	3479000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost	79000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue	80000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Maturities After Ten Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost	0	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Maturities After Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue	0	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	14033000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	13746000	usd
CY2023Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	2400000	usd
CY2022Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	5100000	usd
CY2022Q1	us-gaap	Equity Securities Fv Ni Realized Loss EquitySecuritiesFvNiRealizedLoss	41000000.0	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	3094000	usd
CY2023Q1	bhg	Debt Securities Held To Maturity And Cash And Cash Equivalents Fair Value DebtSecuritiesHeldToMaturityAndCashAndCashEquivalentsFairValue	5276000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	8450000	usd
CY2022Q4	bhg	Debt Securities Held To Maturity And Cash And Cash Equivalents Fair Value DebtSecuritiesHeldToMaturityAndCashAndCashEquivalentsFairValue	11082000	usd
CY2023Q1	us-gaap	Goodwill Gross GoodwillGross	830095000	usd
CY2023Q1	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	70017000	usd
CY2022Q4	us-gaap	Goodwill Gross GoodwillGross	830095000	usd
CY2022Q4	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	70017000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	304882000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	62596000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	304882000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	55799000	usd
CY2022Q1	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	usd
CY2022Q1	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	usd
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	10400000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	20368000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	27025000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	27025000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	27025000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	27025000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	25382000	usd
CY2023Q1	us-gaap	Schedule Of Liability For Unpaid Claims And Claims Adjustment Expense ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense	<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the components of the change in medical costs payable for the three months ended March 31 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(in </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">thousand</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">s)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical costs payable - January 1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">411,753 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263,187 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incurred related to:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">656,599 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">672,697 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,354 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 49pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total incurred</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">686,953 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">672,621 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paid related to:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338,907 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367,504 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301,334 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,143 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 49pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">640,241 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">528,647 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical costs payable - March 31</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">458,465 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407,161 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below details the components making up the medical costs payable as of March 31 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(in </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">thousand</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">s)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims unpaid</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,502 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,329 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider incentive payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,748 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,691 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims adjustment expense liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,823 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,918 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incurred but not reported (IBNR)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338,392 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298,223 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total medical costs payable</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">458,465 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407,161 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>The<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> table below details the components making up the medical costs payable within current liabilities of discontinued operations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(in thousands)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims unpaid</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">61,398</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,477 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider incentive payable</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,717</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,446 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims adjustment expense liability</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,293</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,932 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incurred but not reported (IBNR)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">138,206</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575,930 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total medical costs payable of discontinued operations</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">215,614</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">685,785</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table>
CY2022Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	411753000	usd
CY2021Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	263187000	usd
CY2023Q1	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense	656599000	usd
CY2022Q1	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense	672697000	usd
CY2023Q1	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense	30354000	usd
CY2022Q1	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense	-76000	usd
CY2023Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1	686953000	usd
CY2022Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1	672621000	usd
CY2023Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1	338907000	usd
CY2022Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1	367504000	usd
CY2023Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1	301334000	usd
CY2022Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1	161143000	usd
CY2023Q1	us-gaap	Payments For Losses And Loss Adjustment Expense PaymentsForLossesAndLossAdjustmentExpense	640241000	usd
CY2022Q1	us-gaap	Payments For Losses And Loss Adjustment Expense PaymentsForLossesAndLossAdjustmentExpense	528647000	usd
CY2023Q1	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	458465000	usd
CY2022Q1	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	407161000	usd
CY2023Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Period Increase Decrease LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease	30400000	usd
CY2022Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Period Increase Decrease LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease	-100000	usd
CY2023Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred But Not Reported Ibnr Claims Amount LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount	52502000	usd
CY2022Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred But Not Reported Ibnr Claims Amount LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount	63329000	usd
CY2023Q1	bhg	Liability For Unpaid Claims And Claims Adjustment Expense Claims Adjustment Expense Liability LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsAdjustmentExpenseLiability	61748000	usd
CY2022Q1	bhg	Liability For Unpaid Claims And Claims Adjustment Expense Claims Adjustment Expense Liability LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsAdjustmentExpenseLiability	40691000	usd
CY2023Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Reported Claims Amount LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseReportedClaimsAmount	5823000	usd
CY2022Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Reported Claims Amount LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseReportedClaimsAmount	4918000	usd
CY2023Q1	bhg	Liability For Unpaid Claims And Claims Adjustment Expense Risk Sharing Amounts Payable LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseRiskSharingAmountsPayable	338392000	usd
CY2022Q1	bhg	Liability For Unpaid Claims And Claims Adjustment Expense Risk Sharing Amounts Payable LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseRiskSharingAmountsPayable	298223000	usd
CY2023Q1	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	458465000	usd
CY2022Q1	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	407161000	usd
CY2023Q1	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	46100000	usd
CY2023Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	104900000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	500000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.80
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y10M24D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	64291000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.82
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y8M12D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	82000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
CY2023Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	3000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.63
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	958000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0.58
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	3574000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	1.78
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	61672000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1000	usd
CY2023Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	28800000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-112236000	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-187057000	usd
CY2023Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-74669000	usd
CY2022Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-17115000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-186905000	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-204172000	usd
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	631534000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	631534000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	628765000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	628765000	shares
CY2023Q1	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.18
CY2023Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.18
CY2022Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.30
CY2022Q1	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.30
CY2023Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.12
CY2023Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.12
CY2022Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.02
CY2022Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.02
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.30
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.30
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.32
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.32
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	464084000	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	276618000	shares
CY2023Q1	us-gaap	Loss Contingency Damages Paid Value LossContingencyDamagesPaidValue	0	usd
CY2022	us-gaap	Loss Contingency Damages Paid Value LossContingencyDamagesPaidValue	0	usd
CY2023Q1	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	46100000	usd
CY2023Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	3	segment
CY2023Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2023Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2023Q1	us-gaap	Premiums Earned Net PremiumsEarnedNet	502918000	usd
CY2023Q1	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	239807000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	13570000	usd
CY2023Q1	bhg	Investment Income Loss InvestmentIncomeLoss	46000	usd
CY2023Q1	us-gaap	Revenues Revenues	756341000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-85746000	usd
CY2023Q1	bhg	Depreciation Depletion And Amortization Continuing Operations DepreciationDepletionAndAmortizationContinuingOperations	9891000	usd
CY2023Q1	us-gaap	Restructuring Charges RestructuringCharges	3357000	usd
CY2022Q1	us-gaap	Premiums Earned Net PremiumsEarnedNet	458962000	usd
CY2022Q1	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	182797000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	12392000	usd
CY2022Q1	bhg	Investment Income Loss InvestmentIncomeLoss	-40888000	usd
CY2022Q1	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	0	usd
CY2022Q1	us-gaap	Revenues Revenues	613263000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-159863000	usd
CY2022Q1	bhg	Depreciation Depletion And Amortization Continuing Operations DepreciationDepletionAndAmortizationContinuingOperations	12897000	usd
CY2022Q1	us-gaap	Restructuring Charges RestructuringCharges	6864000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1300000	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3200000	usd
CY2022Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	219758000	usd
CY2021Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	128407000	usd
CY2023Q1	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	1421000	usd
CY2022Q1	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	-2681000	usd
CY2023Q1	bhg	Distribution To Noncontrolling Interest Holders DistributionToNoncontrollingInterestHolders	1805000	usd
CY2022Q1	bhg	Distribution To Noncontrolling Interest Holders DistributionToNoncontrollingInterestHolders	0	usd
CY2023Q1	us-gaap	Minority Interest Period Increase Decrease MinorityInterestPeriodIncreaseDecrease	4129000	usd
CY2022Q1	us-gaap	Minority Interest Period Increase Decrease MinorityInterestPeriodIncreaseDecrease	17285000	usd
CY2023Q1	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	223503000	usd
CY2022Q1	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	143011000	usd
CY2022Q1	bhg	Number Of Direct Contracting Entities NumberOfDirectContractingEntities	3	directcontractingentity
CY2023Q1	bhg	Direct Contracting Risk Mitigation Maximum Percentage Of Performance Year Benchmark DirectContractingRiskMitigationMaximumPercentageOfPerformanceYearBenchmark	0.250
CY2023Q1	bhg	Aco Reach Performance Year Receivable Current ACOReachPerformanceYearReceivableCurrent	882884000	usd
CY2022Q4	bhg	Aco Reach Performance Year Receivable Current ACOReachPerformanceYearReceivableCurrent	99181000	usd
CY2023Q1	bhg	Aco Reach Performance Year Obligation Current ACOReachPerformanceYearObligationCurrent	719420000	usd
CY2022Q4	bhg	Aco Reach Performance Year Obligation Current ACOReachPerformanceYearObligationCurrent	0	usd
CY2023Q1	bhg	Aco Reach Medical Costs Payable ACOReachMedicalCostsPayable	154800000	usd
CY2023Q1	bhg	Aco Reach Prior Year Receivable Current ACOReachPriorYearReceivableCurrent	14900000	usd
CY2023Q1	bhg	Aco Reach Performance Year Receivable Amortization ACOReachPerformanceYearReceivableAmortization	175523000	usd
CY2022Q1	bhg	Aco Reach Performance Year Receivable Amortization ACOReachPerformanceYearReceivableAmortization	75127000	usd
CY2023Q1	bhg	Aco Reach Performance Year Obligation Amortization ACOReachPerformanceYearObligationAmortization	239807000	usd
CY2022Q1	bhg	Aco Reach Performance Year Obligation Amortization ACOReachPerformanceYearObligationAmortization	182797000	usd
CY2023Q1	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	239807000	usd
CY2022Q1	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	182797000	usd
CY2023Q1	bhg	Aco Reach Prior Year Receivable Amortization ACOReachPriorYearReceivableAmortization	84300000	usd
CY2023Q1	us-gaap	Disposal Group Including Discontinued Operation Revenue DisposalGroupIncludingDiscontinuedOperationRevenue	21635000	usd
CY2022Q1	us-gaap	Disposal Group Including Discontinued Operation Revenue DisposalGroupIncludingDiscontinuedOperationRevenue	1187306000	usd
CY2023Q1	us-gaap	Disposal Group Including Discontinued Operation Depreciation And Amortization DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization	0	usd
CY2022Q1	us-gaap	Disposal Group Including Discontinued Operation Depreciation And Amortization DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization	144000	usd
CY2023Q1	us-gaap	Disposal Group Including Discontinued Operation Operating Expense DisposalGroupIncludingDiscontinuedOperationOperatingExpense	96304000	usd
CY2022Q1	us-gaap	Disposal Group Including Discontinued Operation Operating Expense DisposalGroupIncludingDiscontinuedOperationOperatingExpense	1204423000	usd

Files In Submission

Name	View Source	Status
0001628280-23-017232-index-headers.html	Edgar Link	pending
0001628280-23-017232-index.html	Edgar Link	pending
0001628280-23-017232.txt	Edgar Link	pending
0001628280-23-017232-xbrl.zip	Edgar Link	pending
bhg-20230331.htm	Edgar Link	pending
bhg-20230331.xsd	Edgar Link	pending
exhibit102_amendedandresta.htm	Edgar Link	pending
exhibit103_csmithconsultin.htm	Edgar Link	pending
exhibit311_1q23.htm	Edgar Link	pending
exhibit312_1q23.htm	Edgar Link	pending
exhibit321_1q23.htm	Edgar Link	pending
exhibit322_1q23.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
bhg-20230331_cal.xml	Edgar Link	unprocessable
bhg-20230331_def.xml	Edgar Link	unprocessable
bhg-20230331_lab.xml	Edgar Link	unprocessable
bhg-20230331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
bhg-20230331_htm.xml	Edgar Link	completed
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NEUE
NeueHealth, Inc. Stock $neue

2023 Q2 Form 10-Q Financial Statement

#000162828023017232 Filed on May 10, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NEUE NeueHealth, Inc. Stock $neue

2023 Q2 Form 10-Q Financial Statement

#000162828023017232 Filed on May 10, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NEUE
NeueHealth, Inc. Stock $neue